Gliclazide , ≥99% , 21187-98-4

Synonym(s):
N-[[(hexahydrocylopenta[c]pyrrol-2(1H)-yl)amino]carbony]-4-methylbenzene sulfonamide;1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea;Gliclazide

CAS NO.：21187-98-4

Empirical Formula: C15H21N3O3S

Molecular Weight: 323.41

MDL number: MFCD00409893

EINECS: 244-260-5

PRODUCT Properties

• Melting point: 163-169 °C (lit.)
• Density: 1.2205 (rough estimate)
• refractive index: 1.6740 (estimate)
• storage temp.: 2-8°C
• solubility: methylene chloride: soluble
• pka: 6.07±0.10(Predicted)
• form: powder
• color: white
• Merck: 14,4439
• InChI: InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
• InChIKey: BOVGTQGAOIONJV-UHFFFAOYSA-N
• SMILES: C1(S(NC(NN2CC3CCCC3C2)=O)(=O)=O)=CC=C(C)C=C1

Description and Uses

Gliclazide is an oral hypoglycemic agent used to treat non-insulin-dependent diabetes mellitus.Treatment of diabetes associated with obesity or vascular disease, for adults with type 2 diabetes.Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P301+P312+P330
• Hazard Codes: Xn,Xi
• Risk Statements: 21-36/38-46-62-63
• Safety Statements: 25-26-36/37-53-24/25
• RIDADR: 3077
• WGK Germany: 2
• RTECS: YT4500000
• HS Code: 29350090
• Toxicity: LD50 orally in mice: >3 g/kg (Duhault)